Oxaliplatin, Leucovorin, and Fluorouracil With or Without Bevacizumab in Treating Patients Who Have Undergone Surgery for Stage II Colon Cancer
National Cancer Institute (NCI)
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Dana-Farber Cancer Institute
RasCal Therapeutics, Inc.
National Cancer Institute (NCI)
Pfizer
Rutgers, The State University of New Jersey
Copenhagen University Hospital at Herlev
Incyte Corporation
Centre Oscar Lambret
Eli Lilly and Company
Pfizer
GlaxoSmithKline
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University
Roswell Park Cancer Institute
University of California, San Francisco
Vejle Hospital
UNC Lineberger Comprehensive Cancer Center
RemeGen Co., Ltd.
Memorial Sloan Kettering Cancer Center
M.D. Anderson Cancer Center
Alterome Therapeutics, Inc.
NYU Langone Health
Institute of Oncology Ljubljana
The Netherlands Cancer Institute
M.D. Anderson Cancer Center
Xencor, Inc.
City of Hope Medical Center
M.D. Anderson Cancer Center
NRG Oncology
NRG Oncology
Cartography Biosciences
MedImmune LLC
Eastern Cooperative Oncology Group
Pfizer
Kaiser Permanente
Rigshospitalet, Denmark
Accent Therapeutics
Intima Bioscience, Inc.
University Hospital, Clermont-Ferrand
Institute of Oncology Ljubljana
Institute of Oncology Ljubljana
University of Pennsylvania
Duke University
Cedars-Sinai Medical Center
A2 Biotherapeutics Inc.
University Hospital, Rouen
Zealand University Hospital
Mirati Therapeutics Inc.
Arvinas Inc.